Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.US |
First Approval Date21 Sep 2000 |
/ RecruitingNot Applicable A Study Benchmarking FREEDOM Substudy to Evaluate the Effects of Amorphous Calcium Carbonate in Postmenopausal Women
Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.
/ CompletedNot Applicable Effects of Amorphous Calcium Carbonate Supplementation on Bone Health Based on Bone Mineral Density and Bone Turno-ver Markers: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Trial in Postmenopausal Women With Osteopenia
This research was designed in accordance to the Method for Efficacy Assessment of Health Food for Bone Heath. Changes to bone density were measured to evaluate the effectiveness of amorphous calcium carbonate in maintaining bone health.
A Prospective, Randomized, Evaluator Blind, Active-Controlled, Parallel Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to Colonoscopy
The objective is to demonstrate that investigational drug, Quiklean®, is not inferior to standard comparator, Klean-Prep with Dulcolax®, with respect to the overall quality of bowel preparation in subjects undergoing colonoscopy.
100 Clinical Results associated with Universal Integrated Corp. Consumer Products Pte Ltd.
0 Patents (Medical) associated with Universal Integrated Corp. Consumer Products Pte Ltd.
100 Deals associated with Universal Integrated Corp. Consumer Products Pte Ltd.
100 Translational Medicine associated with Universal Integrated Corp. Consumer Products Pte Ltd.